As Tpl2 inhibitors are currently developed by the pharmaceutical industry to treat inflammatory diseases,45, 46 and GLP-1R agonists are approved for treatment of type II diabetes and obesity, our results reinforce the need to first expand the preclinical evaluation of these drugs in animal models of type I and type II diabetes, and then to build new clinical evaluation in patients suffering from diabetes and/or related metabolic disorders. Here, MAP3K8 is linked to diabetes mellitus.